MolecuLight Corp., a leader in point-of-care bacterial fluorescence imaging, announces the acquisition of a Federal Supply Contract from the US Department of Veterans Affairs for its innovative MolecuLight i:X® and DX™ wound imaging devices. 

This contract, facilitated through the VA FSS (Federal Supply Schedule) program, reinforces MolecuLight's commitment to addressing healthcare requirements for Veterans and other federal government agencies.

The VA FSS program, overseeing multiple award Schedule programs for medical equipment, supply, pharmaceutical, and service contracts, plays a pivotal role in providing federal customers with access to a vast array of state-of-the-art commercial products and services. With over 1,700 contracts and an annual sales volume of approximately USD 16 billion, the program ensures comprehensive support for the healthcare needs of Veterans.

"VA patients suffer from all types of wounds, including traumatic, diabetic foot and venous leg ulcers, burns, and surgical site infections, and they deserve the best treatment to help diagnose and treat their ailments and improve their quality of life," emphasizes Anil Amlani, CEO of MolecuLight. 

He highlights the significance of the MolecuLight suite of devices, the only Class II FDA-cleared point-of-care platform capable of detecting harmful bacteria linked to infection, preventing wounds from healing. Amlani underscores the impact of real-time, bedside decisions enabled by MolecuLight devices, ensuring the fastest path to healing for Veterans.

Having provided devices to the VA for several years, the contract is expected to facilitate widespread adoption and accelerated distribution of MolecuLight devices across the entire VA wound care program, aiming to provide optimal care for Veterans.

The MolecuLight i:X and DX stand out as the only Class II FDA-cleared, CE-Marked, and Health Canada approved imaging devices available for the real-time detection of elevated bacterial burden in and around wounds. 

Supported by clinical evidence from over 80 peer-reviewed publications involving 2,600 patients, these devices are globally utilized by leading wound care facilities.